QHSLab, Inc (USAQ) Fair Value & Analysis
Healthcare · US · Market cap $4.5M
Fair value as of: Jun 25, 2026
Analysis
QHSLab, Inc (USAQ) currently trades at $0.3000, while our model-based Fair Value estimate is $0.4900 — implying the stock looks roughly 63.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures. The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine. Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine. The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a p…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is QHSLab, Inc (USAQ) undervalued?
What is the fair value of USAQ?
What is the quality score of USAQ?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.